Hope Smith
Psychiatric/Mental Health · Hopkinsville, KYNPI 1922482587
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,096 of the $68,143 with a category attached, or 76.5%. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 74.0% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $65,154, more than ten times the $13 reported in 2021. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $170.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$50K
- Teva Pharmaceuticals USA, Inc.$14K
- AbbVie$635
- Alkermes, Inc.$592
- Johnson & Johnson$529
- Vanda Pharmaceuticals Inc.$452
- plus $1K from 9 others
What the payments were for
- Consulting fees$2,5004%
- Speaking & faculty fees$52,09676%
- Travel & lodging$6,99110%
- Food & beverage$6,3419%
- Education$2150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 167 | $50,460 |
| Teva Pharmaceuticals USA, Inc. | 35 | $14,273 |
| AbbVie | 41 | $635 |
| Alkermes, Inc. | 34 | $592 |
| Johnson & Johnson | 33 | $529 |
| Vanda Pharmaceuticals Inc. | 20 | $452 |
| Neurocrine Biosciences, Inc. | 19 | $420 |
| E.r. Squibb & Sons, L.L.C. | 22 | $305 |
| Otsuka America Pharmaceutical, Inc. | 7 | $112 |
| Lundbeck LLC | 6 | $110 |
| Axsome Therapeutics, Inc. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 4 | $67 |
| Corium, LLC | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 4 | $35 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,143 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 258 | $887,708 |
| IngrezzaValbenazine Tosylate | 59 | $462,008 |
| CaplytaLumateperone Tosylate | 142 | $238,003 |
| AustedoDeutetrabenazine | 23 | $125,982 |
| LybalviOlanzapine/Samidorphan Malate | 44 | $75,440 |
| OzempicSemaglutide | 69 | $69,087 |
| VraylarCariprazine Hcl | 46 | $66,137 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 91 | $61,231 |
| Abilify MaintenaAripiprazole | 19 | $55,227 |
| Lurasidone Hcl | 194 | $52,576 |
| FanaptIloperidone | 14 | $49,504 |
| EliquisApixaban | 77 | $47,300 |
| LinzessLinaclotide | 79 | $44,239 |
| RexultiBrexpiprazole | 26 | $40,227 |
| JanuviaSitagliptin Phosphate | 67 | $38,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $529 | $887,708258 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $420 | $462,00859 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $50,460 | $238,003142 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $14,273 | $125,98223 claims |
| AbbVieVraylar, Linzess | $635 | $110,376125 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $112 | $95,45445 claims |
| Alkermes, Inc.Lybalvi | $592 | $75,44044 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $452 | $49,50414 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $35 | $33,65723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Hopkinsville
- Rachel ColeHopkinsville$503K
- Brett BondHopkinsville$7K
- Theresa WattsAshland$645K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.